Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

AvePoint’s Lack of Profitability Makes APXT Stock Unattractive

By Larry Ramer, InvestorPlace Contributor

AvePoint is unprofitable and does not seem to have any potentially transformational offerings. As a result, APXT stock is unattractive.

Senseonics Has Too Much Hope for Success Priced in Already

By Larry Ramer, InvestorPlace Contributor

Reddit investors might be weakening, and Senseonics has to contend with a tough competitor, making SENS stock unattractive.

The Risk-Reward Ratio of Zomedica Stock Looks Unfavorable

By Larry Ramer, InvestorPlace Contributor

Zomedica may have to contend with very difficult competition, and there are indications that Truforma is not very popular so far. ZOM stock looks very risky.

It’s Time to Admit Defeat and Dump Ocugen Stock as a Covid Play

By Larry Ramer, InvestorPlace Contributor

After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.

3 (Almost) Penny Stocks Poised to Benefit From the Infrastructure Bill

By Larry Ramer, InvestorPlace Contributor

These three infrastructure companies with penny stocks (or similarly low-price shares) stand to benefit from the upcoming bipartisan bill.

Load More